Rein Therapeutics
RNTX
33 hedge funds and large institutions have $11.8M invested in Rein Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 7 closing their positions.
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
6% more funds holding
Funds holding: 31 → 33 (+2)
0.02% less ownership
Funds ownership: 0.4% → 0.38% (-0.02%)
25% less capital invested
Capital invested by funds: $15.7M → $11.8M (-$3.88M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$258K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$199K |
| 3 |
State Street
Boston,
Massachusetts
|
+$183K |
| 4 |
Squarepoint
New York
|
+$133K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
+$66.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$494K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$401K |
| 3 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
-$401K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$165K |
| 5 |
Bank of New York Mellon
New York
|
-$135K |
RNTX Hedge Fund Activity: Q4 2017 in Review
33 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2017, worth a combined $11.8M — down 25% from $15.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new RNTX positions and 7 closed out — a net gain of 2 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, adding an estimated $258K. The largest seller was Millennium Management, exiting entirely with an estimated $494K sold.
- 33 institutional investors held Rein Therapeutics (RNTX) as of Q4 2017, up from 31 in Q3 2017.
- Funds reported $11.8M of Rein Therapeutics stock for Q4 2017, down 25% quarter-over-quarter.
- 9 funds opened new Rein Therapeutics positions in Q4 2017 and 7 closed out, a net change of +2 holders.
- The largest Rein Therapeutics buyer in Q4 2017 was Vanguard Group, an estimated $258K added.
- The largest Rein Therapeutics seller in Q4 2017 was Millennium Management, an estimated $494K sold.
Based on aggregated 13F filings for Q4 2017.